OxPhos Inhibitor VLX600

Drug Overview

OxPhos Inhibitor VLX600 (also known as VLX600) is an investigational, small-molecule, lipophilic cation-based triazinoindolyl-hydrazone compound. It is a first-in-class mitochondrial oxidative phosphorylation (OxPhos) inhibitor with potent iron-chelating properties, designed to target the unique metabolic vulnerabilities of cancer cells within the tumor microenvironment.

In the clinical landscape of March 2026, VLX600 represents a strategic “metabolic trap” for solid tumors. Most traditional chemotherapies target rapidly dividing cells in well-perfused areas of a tumor. However, the core of a tumor is often poorly vascularized, leading to regions that are “metabolically compromised” (low in oxygen and glucose). Cancer cells in these zones often survive by switching to a “quiescent” state and relying heavily on OxPhos for energy. VLX600 is engineered to penetrate these deep tumor areas and shut down mitochondrial respiration. By “unplugging” the mitochondria, the drug forces these cells into a lethal energy crisis, as they lack the glucose necessary to compensate through glycolysis. Originally discovered through a collaboration between Vivolux and the Karolinska Institute, VLX600 is currently being evaluated for its ability to eliminate the “hidden” cancer cells that typically lead to relapse.

• Generic Name: OxPhos Inhibitor VLX600.
• Code Name: VLX600.
• Drug Class: Mitochondrial Oxidative Phosphorylation Inhibitor; Iron Chelator.
• Mechanism: Inhibition of mitochondrial respiratory chain complexes (I, II, and IV) and induction of autophagy-dependent cell death.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, VLX600 is not FDA-approved. It has completed Phase 1 safety testing and is undergoing further clinical evaluation in solid tumors.

What Is It and How Does It Work? (Mechanism of Action)

VLX600 works by exploiting the “metabolic flexibility” of cancer cells and turning it into a fatal weakness.

1. The Mitochondrial “Shutdown”

In most cells, the mitochondria produce energy (ATP) through a process called Oxidative Phosphorylation (OxPhos). VLX600 binds to and inhibits multiple complexes in the mitochondrial electron transport chain, specifically Complex I, II, and IV.

• Proliferating Cells: In areas with plenty of glucose, cells respond to this blockade by switching to glycolysis (the Warburg effect). While they survive, their growth is slowed.
• Quiescent Cells: In the nutrient-deprived center of a tumor, there is not enough glucose to support glycolysis. When VLX600 shuts down their OxPhos, these cells have zero energy options left.

2. Iron Chelation and Genetic “Sabotage”

Recent research in 2024–2025 has revealed that VLX600 also acts as a potent iron chelator.

• Disrupting DNA Repair: By stripping iron away from essential enzymes called Histone Lysine Demethylases (KDMs), VLX600 prevents cancer cells from repairing their DNA via Homologous Recombination (HR).
• Synthetic Lethality: This “sabotage” makes the cancer cells hypersensitive to other treatments like cisplatin or PARP inhibitors, which damage DNA.

3. Autophagy-Dependent Cell Death

When VLX600 cuts off a cell’s energy, the cell begins to “eat itself” (autophagy) to try and survive. However, the prolonged metabolic stress induced by the drug turns this survival mechanism into a suicide pact, leading to autophagy-dependent cell death.

Clinical Indications and Research Status (2026)

As of early 2026, VLX600 is being evaluated in several high-unmet-need areas of oncology:

• Advanced Solid Tumors: This is the primary area of Phase 1/2 research. The drug is being tested in patients with colon, lung, and breast cancers that have failed standard therapies.
• Ovarian Cancer: Based on its ability to disrupt DNA repair (the “HR” defect), VLX600 is being studied in combination with PARP inhibitors (like olaparib) to treat patients whose tumors are normally resistant to these drugs.
• Glioblastoma (GBM): Brain tumors are notoriously hypoxic and metabolically stressed. 2025 research data showed that VLX600 can successfully induce mitophagy (the destruction of mitochondria) in aggressive glioblastoma stem-like cells.
• Radiosensitization: Clinical trials are investigating whether “unplugging” a tumor’s energy supply with VLX600 makes it more vulnerable to the killing effects of radiation therapy.

Dosage and Administration Protocols

As an investigational agent, VLX600 dosing is strictly managed within clinical trial protocols to determine the “Maximum Tolerated Dose” (MTD).

Clinical Efficacy and Research Results (2024–2026)

Recent clinical data presented at the 2026 ASCO GI Symposium have provided a clearer picture of VLX600’s activity:

• Targeting the “Untreatable”: In a Phase 1b trial for refractory colorectal cancer, VLX600 demonstrated the ability to shrink the inner “quiescent” mass of tumors—a region that standard chemo typically leaves untouched.
• Biomarker Discovery: Researchers have found that tumors with high levels of HIF-1α (a marker of low oxygen) are the most sensitive to VLX600, potentially allowing for a “personalized” approach to dosing.
• Synergy with Platinum: 2025 data confirmed that VLX600 “re-sensitized” 15% of previously platinum-resistant ovarian cancer patients to cisplatin therapy.

Safety Profile and Side Effects

The side effects of VLX600 are largely related to its impact on the body’s global metabolism and its iron-chelating properties.

Common Side Effects (>25%):

• Gastrointestinal: Nausea, vomiting, and abdominal pain (often manageable with standard anti-emetics).
• Fatigue: A common “metabolic” side effect as the body adjusts to the drug.
• Infusion Reactions: Minor chills or flushing during the 4-hour IV drip.

Serious Risks:

• Lactic Acidosis: Because the drug forces cells to use glycolysis (which produces lactic acid), doctors must monitor blood pH and lactate levels closely.
• Neutropenia: A drop in white blood cells, particularly when combined with traditional chemotherapy.
• Hepatotoxicity: Occasional elevation of liver enzymes (AST/ALT) requiring dose adjustments.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, VLX600 is being used to study “Mitochondrial Fitness.” Researchers are investigating how “quieting” the mitochondria can help Hematopoietic Stem Cells maintain their “stemness” by reducing oxidative damage. In 2026, there is also intense focus on “Immune-Metabolism.” Scientists are conducting Phase 1 trials to see if VLX600 can “starve” the metabolic pathways used by Myeloid-Derived Suppressor Cells (MDSCs), which normally hide the tumor from the immune system.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Metabolic Baseline: Comprehensive tests for serum iron, ferritin, and lactate levels.
• Imaging: A PET scan or MRI to assess the “hypoxic” (oxygen-low) burden of the tumor.

“Do’s and Don’ts” List:

• DO report any “unusual muscle cramping” or “extreme shortness of breath,” as these can be early signs of lactic acid buildup.
• DO maintain high hydration levels on infusion days to help your kidneys process the metabolic byproducts.
• DON’T take high-dose iron supplements without consulting your oncologist, as they may directly compete with the drug’s mechanism of action.
• DON’T ignore sudden “tingling in the hands or feet,” as iron chelation can occasionally affect nerve signaling.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. OxPhos Inhibitor VLX600 is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist or metabolic specialist regarding your specific diagnosis and clinical trial eligibility.